カワマタ　タカカズ   KAWAMATA Takakazu   川俣　貴一    所属   医学部 医学科（東京女子医科大学病院）    職種   教授・基幹分野長
論文種別	原著
言語種別	英語
査読の有無	査読あり
表題	Role of a synthetic pyrimidine compound, MS-818, in reduction of infarct size and amelioration of sensorimotor dysfunction following permanent focal cerebral ischemia in rats.
掲載誌名	正式名：Journal of neurosurgery 略　 称：J Neurosurg ISSNコード：0022-3085(Print)0022-3085(Linking)
巻・号・頁	96(6),pp.1072-1076
著者・共著者	Mitsuyama Tetsuryu, Kawamata Takakazu, Yamane Fumitaka, Awaya Akira, Hori Tomokatsu
担当区分	2nd著者,責任著者
発行年月	2002/06
概要	OBJECT:A synthetic heterocyclic pyrimidine compound, MS-818 (2-piperadino-6-methyl-5-oxo-5,6-dihydro-(7H) pyrrolo-[3,4-dOBJECT:]OBJECT:pyrimidine maleate) is reported to have a variety of biological activities including neurite outgrowth, astrocyte differentiation, suppression of neuronal apoptosis, regeneration of injured peripheral nerves, fracture repairs, angiogenesis, and superovulation. To be able to explicate the neurotrophic effects of MS-818, the authors evaluated its effect on the reduction of infarct volume and amelioration of sensorimotor dysfunction in a rat model of focal ischemia.METHODS:Forty male Sprague-Dawley rats were subjected to right middle cerebral artery occlusion and assigned to one of four treatment groups (10 animals in each group). The MS-818 (1, 5, or 10 mg/kg) or phosphate-buffered saline (control group) was administered intraperitoneally at onset of ischemia and again 24 hours later. The rats were killed 48 hours after they underwent surgery to induce stroke, and infarct volume was determined using an image-analysis computer software program following staining with 2,3,5-triphenyltetrazolium chloride. Postischemic neurological deficit and body weight were also assessed.CONCLUSIONS:Significant reductions in infarct volume (total and cortical infarction) were found in all the MS-818-trCONCLUSIONS:eated groups compared with the control group. Furthermore, MS-818 induced significant amelioration of sensorimotor dysfunction, as indicated by the results of forelimb and hindlimb placing tests. The present findings suggest that MS-818, which has a much smaller molecular weight than neurotrophic peptides. represents a new approach to the treatment of focal cerebral ischemia.
DOI	10.3171/jns.2002.96.6.1072
文献番号	12066909